Objective: Triple-negative breast cancer (TNBC) constitutes ∼15% of all diagnosed invasive breast cancer cases with limited options for treatment since immunotherapies that target ER, PR, and HER2 receptors are ineffective. Progesterone (PRG) can induce its effects through either classic, nonclassic, or combined responses by binding to classic nuclear PRG receptors (nPRs) or nonclassic membrane PRG receptors (mPRs). Under PRG-induced actions, we previously demonstrated that the CCM signaling complex (CSC) can couple both nPRs and mPRs into a CmPn signaling network, which plays an important role during nPR(+) breast cancer tumorigenesis. We recently defined the novel CmP signaling network in African American women (AAW)-derived TNBC cells, which overlapped with our previously defined CmPn network in nPR(+) breast cancer cells.
Methods: Under mPR-specific steroid actions, we measured alterations to key tumorigenic pathways in Caucasian American women (CAW)- derived TNBC cells, with RNAseq/proteomic and systems biology approaches. Exemption from ethics approval from IRB: This study only utilized cultured NBC cell lines with publicly available TNBC clinical data sets.
Results: Our results demonstrated that TNBCs in CAW share similar altered signaling pathways, as TNBCs in AAW, under mPR-specific steroid actions, demonstrating the overall aggressive nature of TNBCs, regardless of racial differences. Furthermore, in this report, we have deconvoluted the CmP signalosome, using systems biology approaches and CAW-TNBC clinical data, to identify 21 new CAW-TNBC-specific prognostic biomarkers that reinforce the definitive role of CSC and mPR signaling during CAW-TNBC tumorigenesis.
Conclusion: This new set of potential prognostic biomarkers may revolutionize molecular mechanisms and currently known concepts of tumorigenesis in CAW-TNBCs, leading to hopeful new therapeutic strategies.
Get full access to this article
View all access options for this article.
References
1.
Abou-FadelJ, GrajedaB, JiangX, et al. (2021) CmP signaling network unveils novel biomarkers for triple negative breast cancer in African American women. bioRxiv 2021.05.24.445510.
2.
Abou-FadelJ, JiangX, GrajedaB, et al. (2020a) CCM signaling complex (CSC) coupling both classic and non-classic progesterone receptor signaling. bioRxiv. doi: https://doi.org/10.1101/2020.05.24.112847, SSRN: https://ssrn.com/abstract=3881307 or http://dx.doi.org/10.2139/ssrn.3881307
3.
Abou-FadelJ, JiangX, PadartiA, et al. (2020b) CCM signaling complex (CSC) is a master regulator governing homeostasis of progesterone and its mediated signaling cascades. bioRxiv. doi: https://doi.org/10.1101/2020.06.10.145003
4.
Abou-FadelJ, QuY, GonzalezEM, et al. (2020c) Emerging roles of CCM genes during tumorigenesis with potential application as novel biomarkers across major types of cancers. Oncol Rep, 43:1945-1963.
Abou-FadelJ, VasquezM, GrajedaB, et al. (2019) Systems-wide analysis unravels the new roles of CCM signal complex (CSC). Heliyon, 5:e02899.
7.
Abou-FadelJ, ZhangJ (2020) Systems wide analysis of CCM signaling complex alterations in CCM-deficient models using omics approaches. Methods Mol Biol, 2152:325-344.
8.
AhmadA (2019) Breast cancer statistics: recent trends. Adv Exp Med Biol, 1152:1-7.
9.
AnastasJN, MoonRT (2013) WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer, 13:11-26.
10.
AndreF, IsmailaN, HenryNL, et al. (2019) Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update-Integration of Results From TAILORx. J Clin Oncol, 37:1956-1964.
11.
AzumaK, KawaharaA, HattoriS, et al. (2012) NDRG1/Cap43/Drg-1 may predict tumor angiogenesis and poor outcome in patients with lung cancer. J Thorac Oncol, 7:779-789.
12.
BalkwillF (2004) Cancer and the chemokine network. Nat Rev Cancer, 4:540-550.
13.
BaltzerPAT, BenndorfM, DietzelM, et al. (2010) False-positive findings at contrast-enhanced breast MRI: A BI-RADS Descriptor Study. Am J Roentgenol, 194:1658-1663.
14.
BaquetCR, MishraSI, CommiskeyP, et al. (2008) Breast cancer epidemiology in blacks and whites: disparities in incidence, mortality, survival rates and histology. J Natl Med Assoc, 100:480-488.
15.
BerghJJ, LinHY, LansingL, et al. (2005) Integrin alphaVbeta3 contains a cell surface receptor site for thyroid hormone that is linked to activation of mitogen-activated protein kinase and induction of angiogenesis. Endocrinology, 146:2864-2871.
16.
CareyLA, PerouCM, LivasyCA, et al. (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA, 295:2492-2502.
17.
CecconiF, GrussP (2001) Human Genome and Diseases:Apaf1 in developmental apoptosis and cancer: how many ways to die? Cell Mol Life Sci 58:1688-1697.
18.
ChaconRD, CostanzoMV (2010) Triple-negative breast cancer. Breast Cancer Res 12 Suppl, 2:S3.
19.
CharlesNJ, ThomasP, LangeCA (2010) Expression of membrane progesterone receptors (mPR/PAQR) in ovarian cancer cells: implications for progesterone-induced signaling events. Horm Cancer, 1:167-176.
20.
ChenX, LiJ, GrayWH, LehmannBD, et al. (2012) TNBCtype: a subtyping tool for triple-negative breast cancer. Cancer Inform, 11:147-156.
21.
ChowMT, LusterAD (2014) Chemokines in cancer. Cancer Immunol Res, 2:1125-1131.
22.
ChristieM, JorissenRN, MouradovD, et al. (2013) Different APC genotypes in proximal and distal sporadic colorectal cancers suggest distinct WNT/β-catenin signalling thresholds for tumourigenesis. Oncogene, 32:4675-4682.
23.
ColomerR, Aranda-LopezI, AlbanellJ, et al. (2018) Biomarkers in breast cancer: a consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology. Clin Transl Oncol, 20:815-826.
24.
CostaRLB, GradisharWJ (2017) Triple-negative breast cancer: current practice and future directions. J Oncol Pract, 13:301-303.
25.
CoussensLM, WerbZ (2002) Inflammation and cancer. Nature, 420:860-867.
26.
DaiX, ChengH, BaiZ, LiJ (2017) Breast cancer cell line classification and its relevance with breast tumor subtyping. J Cancer, 8:3131-3141.
27.
DavisonC, MorelliR, KnowlsonC, et al. (2021) Targeting nucleotide metabolism enhances the efficacy of anthracyclines and anti-metabolites in triple-negative breast cancer. NPJ Breast Cancer, 7:38.
28.
DignamJJ (2000) Differences in breast cancer prognosis among African-American and Caucasian women. CA Cancer J Clin, 50:50-64.
29.
DongolS, ZhangQ, QiuC, et al. (2020) IQGAP3 promotes cancer proliferation and metastasis in high-grade serous ovarian cancer. Oncol Lett, 20:1179-1192.
30.
DosiouC, HamiltonAE, PangY, et al. (2008) Expression of membrane progesterone receptors on human T lymphocytes and Jurkat cells and activation of G-proteins by progesterone. J Endocrinol, 196:67-77.
31.
DressingGE, AlyeaR, PangY, ThomasP (2012) Membrane progesterone receptors (mPRs) mediate progestin induced antimorbidity in breast cancer cells and are expressed in human breast tumors. Horm Cancer, 3:101-112.
32.
DressingGE, ThomasP (2007) Identification of membrane progestin receptors in human breast cancer cell lines and biopsies and their potential involvement in breast cancer. Steroids, 72:111-116.
33.
El AnsariR, CrazeML, Diez-RodriguezM, et al. (2018) The multifunctional solute carrier 3A2 (SLC3A2) confers a poor prognosis in the highly proliferative breast cancer subtypes. Br J Cancer, 118:1115-1122.
34.
EngelmanJA, ZhangXL, RazaniB, et al. (1999) p42/44 MAP Kinase-dependent and -independent Signaling Pathways Regulate Caveolin-1 Gene Expression: ACTIVATION OF RAS-MAP KINASE AND PROTEIN KINASE A SIGNALING CASCADES TRANSCRIPTIONALLY DOWN-REGULATES CAVEOLIN-1 PROMOTER ACTIVITY*. J Biol Chem, 274:32333-32341.
35.
Esquivel-VelazquezM, Ostoa-SalomaP, Palacios-ArreolaMI, et al. (2015) The role of cytokines in breast cancer development and progression. J Interferon Cytokine Res, 35:1-16.
36.
FarshidG, WaltersD (2018) Molecular subtypes of screen-detected breast cancer. Breast Cancer Res Treat, 172:191-199.
37.
FaschingPA, BruckerSY, FehmTN, et al. (2015) Biomarkers in Patients with Metastatic Breast Cancer and the PRAEGNANT Study Network. Geburtshilfe Frauenheilkd, 75:41-50.
38.
FjelldalR, MoeBT, ØrboA, SagerG (2010) MCF-7 cell apoptosis and cell cycle arrest: non-genomic effects of progesterone and mifepristone (RU-486). Anticancer Res, 30:4835-4840.
39.
FreeseJL, PinoD, PleasureSJ (2010) Wnt signaling in development and disease. Neurobiol Dis, 38:148-153.
40.
GeSX, SonEW, YaoR (2018) iDEP: an integrated web application for differential expression and pathway analysis of RNA-Seq data. BMC Bioinform, 19:534.
41.
GhoshJ, ChatterjeeM, GangulyS, et al. (2021) PDL1 expression and its correlation with outcomes in non-metastatic triple-negative breast cancer (TNBC). Ecancermedicalscience, 15:1217.
42.
GilkesDM, BajpaiS, WongCC, et al. (2013) Procollagen lysyl hydroxylase 2 is essential for hypoxia-induced breast cancer metastasis. Mol Cancer Res, 11:456-466.
43.
GoelHL, BreenM, ZhangJ, et al. (2005) beta1A integrin expression is required for type 1 insulin-like growth factor receptor mitogenic and transforming activities and localization to focal contacts. Cancer Res, 65:6692-6700.
44.
GoldmanMJ, CraftB, HastieM, et al. (2020) Visualizing and interpreting cancer genomics data via the Xena platform. Nat Biotechnol, 38:675-678.
45.
GyorffyB, LanczkyA, EklundAC, et al. (2010) An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat, 123:725-731.
HisadaY, MackmanN (2019) Tissue factor and cancer: regulation, tumor growth, and metastasis. Semin Thromb Hemost, 45:385-395.
48.
HowardFM, OlopadeOI (2021) Epidemiology of triple-negative breast cancer: a review. Cancer J, 27:8-16.
49.
HuangF, ZhangQ, MaH, et al. (2014) Expression of glutaminase is upregulated in colorectal cancer and of clinical significance. Int J Clin Exp Pathol, 7:1093-1100.
50.
HuangM, QinX, WangY, MaoF (2020) Identification of AK4 as a novel therapeutic target for serous ovarian cancer. Oncol Lett, 20:346.
51.
HuangX-P, RongT-H, WuQ-L, et al. (2005) MCM4 expression in esophageal cancer from southern China and its clinical significance. J Cancer Res Clin Oncol, 131:677-682.
52.
HuangX, LiX, XieX, et al. (2016) High expressions of LDHA and AMPK as prognostic biomarkers for breast cancer. Breast, 30:39-46.
53.
IrvinWJ, Jr., CareyLA (2008) What is triple-negative breast cancer? Eur J Cancer 44:2799-2805.
54.
JemalA, SiegelR, WardE, et al. (2009) Cancer statistics, 2009. CA Cancer J Clin, 59:225-249.
55.
JiangX, PadartiA, QuY, et al. (2019) Alternatively spliced isoforms reveal a novel type of PTB domain in CCM2 protein. Sci Rep, 9:15808.
56.
JuanJ, MuraguchiT, IezzaG, et al. (2014) Diminished WNT -> β-catenin -> c-MYC signaling is a barrier for malignant progression of BRAFV600E-induced lung tumors. Genes Dev, 28:561-575.
57.
KarterisE, ZervouS, PangY, et al. (2006) Progesterone signaling in human myometrium through two novel membrane G protein-coupled receptors: potential role in functional progesterone withdrawal at term. Mol Endocrinol, 20:1519-1534.
58.
KikuchiJ, KinoshitaI, ShimizuY, et al. (2011) Minichromosome maintenance (MCM) protein 4 as a marker for proliferation and its clinical and clinicopathological significance in non-small cell lung cancer. Lung Cancer, 72:229-237.
59.
KiyozumiY, IwatsukiM, KurashigeJ, et al. (2018) PLOD2 as a potential regulator of peritoneal dissemination in gastric cancer. Int J Cancer, 143:1202-1211.
60.
KlopockiE, KristiansenG, WildPJ, et al. (2004) Loss of SFRP1 is associated with breast cancer progression and poor prognosis in early stage tumors. Int J Oncol, 25:641-649.
61.
KropI, IsmailaN, AndreF, et al. (2017a) Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update. J Clin Oncol, 35:2838-2847.
62.
KropI, IsmailaN, StearnsV (2017b) Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Focused Update Guideline Summary. J Oncol Pract, 13:763-766.
63.
LangeCA, YeeD (2008) Progesterone and breast cancer. Womens Health (Lond), 4:151-162.
64.
LehmannBD, BauerJA, ChenX, et al. (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest, 121:2750-2767.
65.
LentoW, CongdonK, VoermansC, et al. (2013) Wnt signaling in normal and malignant hematopoiesis. Cold Spring Harb Perspect Biol, 5:a008011.
66.
LiB, ChuX, GaoM, XuY (2011) The effects of CD59 gene as a target gene on breast cancer cells. Cell Immunol, 272:61-70.
67.
LiS, LiS, SunY, LiL (2014) The expression of β-catenin in different subtypes of breast cancer and its clinical significance. Tumour Biol, 35:7693-7698.
68.
LiangX, LiH, CoussyF, et al. (2019) An update on biomarkers of potential benefit with bevacizumab for breast cancer treatment: do we make progress?. Chin J Cancer Res, 31:586-600.
69.
LiangY, HouM, KallabAM, et al. (2003) Induction of antiproliferation and apoptosis in estrogen receptor negative MDA-231 human breast cancer cells by mifepristone and 4-hydroxytamoxifen combination therapy: a role for TGFbeta1. Int J Oncol, 23:369-380.
70.
LinSY, XiaW, WangJC, et al. (2000) Beta-catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression. Proc Natl Acad Sci U S A, 97:4262-4266.
71.
LiuR, ShiP, NieZ, et al. (2016) Mifepristone Suppresses Basal Triple-Negative Breast Cancer Stem Cells by Down-regulating KLF5 Expression. Theranostics, 6:533-544.
72.
LivasyCA, KaracaG, NandaR, et al. (2006) Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol, 19:264-271.
73.
LuisTC, IchiiM, BrugmanMH, et al. (2012) Wnt signaling strength regulates normal hematopoiesis and its deregulation is involved in leukemia development. Leukemia, 26:414-421.
74.
MaoX-Y, FanC-F, WeiJ, et al. (2011) Increased N-myc downstream-regulated gene 1 expression is associated with breast atypia-to-carcinoma progression. Tumor Biol, 32:1271.
75.
MasisiBK, El AnsariR, AlfarsiL, et al. (2020) The role of glutaminase in cancer. Histopathology, 76:498-508.
76.
MellacheruvuD, WrightZ, CouzensAL, et al. (2013) The CRAPome: a contaminant repository for affinity purification-mass spectrometry data. Nat Methods, 10:730-736.
77.
MiH, EbertD, MuruganujanA, et al. (2021) PANTHER version 16: a revised family classification, tree-based classification tool, enhancer regions and extensive API. Nucleic Acids Res, 49:D394-D403.
78.
MiroliubovBM, MiroliubovLM (1991) [The possibilities of improving the quality of venous autotransplants]. Grud Serdechnososudistaia Khir, 3:39-43.
79.
MoeBG, VereideAB, OrboA, SagerG (2009) High concentrations of progesterone and mifepristone mutually reinforce cell cycle retardation and induction of apoptosis. Anticancer Res, 29:1053-1058.
80.
MustacchiG, De LaurentiisM (2015) The role of taxanes in triple-negative breast cancer: literature review. Drug Des Devel Ther, 9:4303-4318.
81.
NarayanAK, LeeCI, LehmanCD (2020) Screening for breast cancer. Med Clin North Am, 104:1007-1021.
82.
NeveRM, ChinK, FridlyandJ, et al. (2006) A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell, 10:515-527.
83.
NewmanLA (2014) Breast cancer disparities: high-risk breast cancer and African ancestry. Surg Oncol Clin N Am, 23:579-592.
84.
NewmanLA, KaljeeLM (2017) Health disparities and triple-negative breast cancer in African American Women: a review. JAMA Surg, 152:485-493.
85.
PangY, ThomasP (2011) Progesterone signals through membrane progesterone receptors (mPRs) in MDA-MB-468 and mPR-transfected MDA-MB-231 breast cancer cells which lack full-length and N-terminally truncated isoforms of the nuclear progesterone receptor. Steroids, 76:921-928.
86.
PawlikowskiJS, McBryanT, van TuynJ, et al. (2013) Wnt signaling potentiates nevogenesis. Proc Natl Acad Sci U S A, 110:16009-16014.
87.
PerouCM, SorlieT, EisenMB, et al. (2000) Molecular portraits of human breast tumours. Nature, 406:747-752.
88.
PerrettRM, McArdleCA (2013) Molecular mechanisms of gonadotropin-releasing hormone signaling: integrating cyclic nucleotides into the network. Front Endocrinol (Lausanne), 4:180.
89.
PlevritisSK, MunozD, KurianAW, et al. (2018) Association of screening and treatment with breast cancer mortality by molecular subtype in US Women, 2000-2012. JAMA, 319:154-164.
90.
PolakisP (2012) Wnt signaling in cancer. Cold Spring Harb Perspect Biol, 4:a008052.
91.
PrakashO, HossainF, DanosD, et al. (2020) Racial disparities in triple negative breast cancer: a review of the role of biologic and non-biologic factors. Front Public Health, 8:576964.
92.
ProvencherL, HogueJC, DesbiensC, et al. (2016) Is clinical breast examination important for breast cancer detection?. Curr Oncol, 23:e332-e339.
93.
QianX-L, PanY-H, HuangQ-Y, et al. (2019) Caveolin-1: a multifaceted driver of breast cancer progression and its application in clinical treatment. OncoTargets Ther, 12:1539-1552.
94.
Romero-SanchezM, PeiperSC, EvansB, et al. (2008) Expression profile of heptahelical putative membrane progesterone receptors in epithelial ovarian tumors. Hum Pathol, 39:1026-1033.
95.
SalehM, ChandrashekarDS, ShahinS, et al. (2021) Comparative analysis of triple-negative breast cancer transcriptomics of Kenyan, African American and Caucasian Women. Transl Oncol, 14:101086.
96.
SchallyAV (1999) Luteinizing hormone-releasing hormone analogs: their impact on the control of tumorigenesis. Peptides, 20:1247-1262.
97.
SchmidtM, FaschingPA, BeckmannMW, KolblH (2012) Biomarkers in Breast Cancer - An Update. Geburtshilfe Frauenheilkd, 72:819-832.
98.
SchröderJ, SchumacherU, BöckelmannLC (2020) Thioredoxin interacting protein (TXNIP) is differentially expressed in human tumor samples but is absent in human tumor cell line xenografts: implications for its use as an immunosurveillance marker. Cancers, 12:3028.
99.
SekineC, NakanoS, MibuA, et al. (2020) Breast cancer hormone receptor negativity, triple-negative type, mastectomy and not receiving adjuvant radiotherapy were associated with axillary recurrence after sentinel lymph node biopsy. Asian J Surg, 43:148-153.
100.
SharmaP (2018) Update on the treatment of early-stage triple-negative breast cancer. Curr Treat Options Oncol, 19:22.
101.
ShengX, LiY, LiY, et al. (2019) PLOD2 contributes to drug resistance in laryngeal cancer by promoting cancer stem cell-like characteristics. BMC Cancer, 19:840.
102.
SleiterN, PangY, ParkC, et al. (2009) Progesterone receptor A (PRA) and PRB-independent effects of progesterone on gonadotropin-releasing hormone release. Endocrinology, 150:3833-3844.
103.
SonD, KimY, LimS, et al. (2019) miR-374a-5p promotes tumor progression by targeting ARRB1 in triple negative breast cancer. Cancer Lett, 454:224-233.
104.
ThomasP (2008) Characteristics of membrane progestin receptor alpha (mPRalpha) and progesterone membrane receptor component 1 (PGMRC1) and their roles in mediating rapid progestin actions. Front Neuroendocrinol, 29:292-312.
105.
ThorssonV, GibbsDL, BrownSD, et al. (2018) The immune landscape of cancer. Immunity, 48:812-830 e14.
106.
ToftDJ, CrynsVL (2011) Minireview: basal-like breast cancer: from molecular profiles to targeted therapies. Mol Endocrinol, 25:199-211.
107.
TropI, LeBlancSM, DavidJ, et al. (2014) Molecular classification of infiltrating breast cancer: toward personalized therapy. Radiographics, 34:1178-1195.
108.
VieiraAF, SchmittF (2018) An update on breast cancer multigene prognostic tests-emergent clinical biomarkers. Front Med (Lausanne), 5:248.
109.
Villarreal-GarzaC, KhalafD, BouganimN, et al. (2014) Platinum-based chemotherapy in triple-negative advanced breast cancer. Breast Cancer Res Treat, 146:567-572.
110.
WangL, ShalekAK, LawrenceM, et al. (2014) Somatic mutation as a mechanism of Wnt/β-catenin pathway activation in CLL. Blood, 124:1089-1098.
111.
WebsterMR, XuM, KinzlerKA, et al. (2015) Wnt5A promotes an adaptive, senescent-like stress response, while continuing to drive invasion in melanoma cells. Pigment Cell Melanoma Res, 28:184-195.
112.
WrightRH, CastellanoG, BonetJ, et al. (2012) CDK2-dependent activation of PARP-1 is required for hormonal gene regulation in breast cancer cells. Genes Dev, 26:1972-1983.
113.
WuHJ, ChuPY (2021) Recent discoveries of macromolecule- and cell-based biomarkers and therapeutic implications in breast cancer. Int J Mol Sci, 22:636.
114.
XieM, ZhouL, ChenX, et al. (2015) Progesterone and Src family inhibitor PP1 synergistically inhibit cell migration and invasion of human basal phenotype breast cancer cells. Biomed Res Int, 2015:426429.
115.
XieM, ZhuX, LiuZ, et al. (2012) Membrane progesterone receptor alpha as a potential prognostic biomarker for breast cancer survival: a retrospective study. PLoS One, 7:e35198.
116.
XiongG, StewartRL, ChenJ, et al. (2018) Collagen prolyl 4-hydroxylase 1 is essential for HIF-1α stabilization and TNBC chemoresistance. Nat Commun, 9:4456-4456.
117.
XuR (2019) P4HA1 is a new regulator of the HIF-1 pathway in breast cancer. Cell Stress, 3:27-28.
118.
XuW, XuB, YaoY, et al. (2016) Overexpression and biological function of IQGAP3 in human pancreatic cancer. Am J Transl Res, 8:5421-5432.
119.
YangY, WangJ, XuS, et al. (2021) IKBIP is a novel EMT-related biomarker and predicts poor survival in glioma. Transl Neurosci, 12:009-019.
120.
ZhanT, RindtorffN, BoutrosM (2017) Wnt signaling in cancer. Oncogene, 36:1461-1473.
121.
ZhangJ, DubeyP, PadartiA, et al. (2017) Novel functions of CCM1 delimit the relationship of PTB/PH domains. Biochim Biophys Acta Proteins Proteom, 1865:1274-1286.
122.
ZhangJ, YinY-T, WuC-H, et al. (2019) AK4 promotes the progression of HER2-positive breast cancer by facilitating cell proliferation and invasion. Dis Markers, 2019:8186091.
123.
ZhangN, LiuL, FanN, et al. (2016) The requirement of SEPT2 and SEPT7 for migration and invasion in human breast cancer via MEK/ERK activation. Oncotarget, 7:61587-61600.
124.
ZhuY, ZhuX, TangC, et al. (2021) Progress and challenges of immunotherapy in triple-negative breast cancer. Biochim Biophys Acta Rev Cancer, 1876:188593.
125.
ZillerF, MacorP, BullaR, et al. (2005) Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement-regulatory proteins CD55 and CD59. Eur J Immunol, 35:2175-2183.
126.
ZimmerliD, HausmannG, CantuC, BaslerK (2017) Pharmacological interventions in the Wnt pathway: inhibition of Wnt secretion versus disrupting the protein-protein interfaces of nuclear factors. Br J Pharmacol, 174:4600-4610.
127.
ZuoL, LiW, YouS (2010) Progesterone reverses the mesenchymal phenotypes of basal phenotype breast cancer cells via a membrane progesterone receptor mediated pathway. Breast Cancer Res, 12:R34.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
